News

Newer antihypertensive therapy reduces cardiovascular events

BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7516.533-a (Published 08 September 2005) Cite this as: BMJ 2005;331:533
  1. Susan Mayor
  1. London

    Antihypertensive therapy based on the calcium channel blocker amlodipine, with the angiotensin converting enzyme inhibitor perindopril added as required, reduced cardiovascular events compared with treatment based on the β blocker atenolol, according to the final results from the Anglo-Scandinavian cardiac out-comes trial-blood pressure lowering arm (ASCOT-BPLA) trial published online this week in the Lancet (http://www.lancet.com/, doi:10.1016/S0140-6736(05)67186-3).

    The trial randomised 19 257 hypertensive patients aged 40-79 years with at least three other cardiovascular risk factors to one of two antihypertensive regimens—amlodipine (5-10 mg) with or without perindopril (4-8 mg), or atenolol (50-100 mg) with or without the …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe